MoonLake Immunotherapeutics
NASDAQ: MLTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jorge Santos da Silva
- Employees
- 100
- Headquarters
- Zug, Switzerland
- IPO year
- 2020
- Market cap
- $1.5B
- Website
- https://www.moonlaketx.com
Loading MLTX…
Loading profile data…Frequently asked questions about MLTX
What does MoonLake Immunotherapeutics (MLTX) do?
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is...
Where does MLTX trade?
MoonLake Immunotherapeutics (MLTX) trades on the NASDAQ Capital Market.
What sector is MLTX in?
MoonLake Immunotherapeutics (MLTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of MoonLake Immunotherapeutics?
Jorge Santos da Silva is the chief executive officer of MoonLake Immunotherapeutics (MLTX).
Where is MoonLake Immunotherapeutics headquartered?
MoonLake Immunotherapeutics is headquartered in Switzerland.
Does MLTX pay a dividend?
MoonLake Immunotherapeutics (MLTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MLTX go public?
MoonLake Immunotherapeutics (MLTX) completed its initial public offering in 2020.